<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>177(24)</volume><submitter>van Wijk RC</submitter><pubmed_abstract>&lt;h4>Background and purpose&lt;/h4>There is a clear need for innovation in anti-tuberculosis drug development. The zebrafish larva is an attractive disease model in tuberculosis research. To translate pharmacological findings to higher vertebrates, including humans, the internal exposure of drugs needs to be quantified and linked to observed response.&lt;h4>Experimental approach&lt;/h4>In zebrafish studies, drugs are usually dissolved in the external water, posing a challenge to quantify internal exposure. We developed experimental methods to quantify internal exposure, including nanoscale blood sampling, and to quantify the bacterial burden, using automated fluorescence imaging analysis, with isoniazid as the test compound. We used pharmacokinetic-pharmacodynamic modelling to quantify the exposure-</pubmed_abstract><journal>British journal of pharmacology</journal><pagination>5518-5533</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7707096</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Anti-tuberculosis effect of isoniazid scales accurately from zebrafish to humans.</pubmed_title><pmcid>PMC7707096</pmcid><pubmed_authors>Krekels EHJ</pubmed_authors><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Bahi R</pubmed_authors><pubmed_authors>Hu W</pubmed_authors><pubmed_authors>Verbeek FJ</pubmed_authors><pubmed_authors>Dijkema SM</pubmed_authors><pubmed_authors>Spaink HP</pubmed_authors><pubmed_authors>van den Berg DJ</pubmed_authors><pubmed_authors>van Wijk RC</pubmed_authors><pubmed_authors>Simonsson USH</pubmed_authors><pubmed_authors>van der Graaf PH</pubmed_authors></additional><is_claimable>false</is_claimable><name>Anti-tuberculosis effect of isoniazid scales accurately from zebrafish to humans.</name><description>&lt;h4>Background and purpose&lt;/h4>There is a clear need for innovation in anti-tuberculosis drug development. The zebrafish larva is an attractive disease model in tuberculosis research. To translate pharmacological findings to higher vertebrates, including humans, the internal exposure of drugs needs to be quantified and linked to observed response.&lt;h4>Experimental approach&lt;/h4>In zebrafish studies, drugs are usually dissolved in the external water, posing a challenge to quantify internal exposure. We developed experimental methods to quantify internal exposure, including nanoscale blood sampling, and to quantify the bacterial burden, using automated fluorescence imaging analysis, with isoniazid as the test compound. We used pharmacokinetic-pharmacodynamic modelling to quantify the exposure-</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Dec</publication><modification>2026-07-16T07:17:26.121Z</modification><creation>2021-02-20T09:58:10Z</creation></dates><accession>S-EPMC7707096</accession><cross_references><pubmed>32860631</pubmed><doi>10.1111/bph.15247</doi></cross_references></HashMap>